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In addition to CD4+ regulatoryT cells (Tregs), CD8+ suppressorT cells are emerging as an
important subset of regulatoryT cells. Diverse populations of CD8+T cells with suppressive
activities have been described. Among them, a small population of CD8+CD25+FOXP3+ T
cells is found both in mice and humans. In contrast to thymic-derived CD4+CD25+FOXP3+
Tregs, their origin and their role in the pathophysiology of autoimmune diseases (AIDs) are
less understood. We report here the number, phenotype, and function of CD8+ Tregs cells
in mice and humans, at the steady state and in response to low-dose interleukin-2 (IL-2).
CD8+ Tregs represent approximately 0.4 and 0.1% of peripheral blood T cells in healthy
humans and mice, respectively. In mice, their frequencies are quite similar in lymph nodes
(LNs) and the spleen, but two to threefold higher in Peyer patches and mesenteric LNs.
CD8+ Tregs express low levels of CD127. CD8+ Tregs express more activation or prolif-
eration markers such as CTLA-4, ICOS, and Ki-67 than other CD8+ T cells. In vitro, they
suppress effector T cell proliferation as well as or even better than CD4+ Tregs. Owing to
constitutive expression of CD25, CD8+ Tregs are 20- to 40-fold more sensitive to in vitro
IL-2 stimulation than CD8+ effector T cells, but 2–4 times less than CD4+ Tregs. Neverthe-
less, low-dose IL-2 dramatically expands and activates CD8+ Tregs even more than CD4+
Tregs, in mice and humans. Further studies are warranted to fully appreciate the clinical
relevance of CD8+ Tregs in AIDs and the efficacy of IL-2 treatment.
Keywords: immunological tolerance, immunotherapy, autoimmunity,T cell biology, immune response
INTRODUCTION
T cell development in the thymus comprises the positive selection
of functional T cells capable of supporting adaptive immunity and
the elimination of highly self-reactive T cells. The latter process is
leaky and some autoreactive effector T cells (Teffs) escape into
the periphery where they are regulated by peripheral tolerance
mechanisms. In healthy individuals, multiple cell subsets with
immunoregulatory properties, among CD4+ and CD8+ T cell or
B cell populations, control these potentially harmful Teffs (1–3).
The best characterized of such regulatory cell populations
are the natural CD4+CD25+FOXP3+ thymic-derived regulatory
T cells (CD4+ Tregs). Their major role in the maintenance of
immunological self-tolerance and immune homeostasis (4, 5)
is illustrated by the rapid development of autoimmune diseases
(AIDs) in normal mice upon their depletion (4) and also by
the occurrence of severe AID, allergy, and immunopathology in
humans with a mutated FOXP3 gene (6). CD4+ Treg biology has
dominated research on regulatory cells in AIDs. More recently,
other regulatory cell populations have received attention, and
notably CD8+ suppressor cells (CD8+ Tsups) for which evidence
that they are involved in AIDs is growing (7–9). However, CD8+
Tsups are less well characterized than CD4+ Tregs.
CD8+ Tsups are functionally defined populations of CD8+
T cells endowed with immunosuppressive functions (10–14).
Several subpopulations of CD8+ Tsups have been described based
on the expression of CD8αα, CD25, CD38, CD45RA, CD45RO,
CD56, FOXP3, CXCR3, LAG-3, CD103, CD122, and/or HLA-G,
as well as the absence of CD28 and CD127 (2, 7, 8, 15). The
different CD8+ Tsup subsets are multiply involved in the patho-
physiology of different AIDs (16). Their suppressive activity in
AIDs was first demonstrated in CD8-depleted mice, which were
more susceptible to a second induction of experimental autoim-
mune encephalomyelitis (17). CD8-deficient mice were also more
susceptible to relapse of autoimmune arthritis after immuniza-
tion with self-antigens (18). In non-obese diabetic mice, antigen-
specific CD8+ Tsups were able to not only prevent but also reverse
type 1 diabetes (15). Notably, in patients with systemic lupus ery-
thematosus (19–21), inflammatory bowel disease (22), or multiple
sclerosis (23–26) defective functions and/or reduced numbers of
CD8+ Tsups have been reported. CD8+ Tsup biology is also less
well known than that of CD4+ Tregs, due in part to their small
numbers, which render functional studies difficult.
Only some CD8+ Tsups express FOXP3, the master regulator
of CD4+ Treg differentiation and function, as well as CD25, and
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will be referred to here as CD8+ Tregs. Many groups are now
suggesting that FOXP3 expression might represent a good indi-
cator of a bona fide suppressive function (7, 27–30). Notably, it
was demonstrated in lupus-prone mice that silencing FOXP3 with
siRNA abrogates the ability of CD8+ Tregs to suppress anti-DNA
antibodies (27, 29).
As CD8+ Tregs express CD25, the question of their sensitivity
to interleukin-2 (IL-2) is relevant. Stimulation with IL-2 is indeed
crucial for CD4+ Tregs. Mice deficient in IL-2 or in IL-2 receptor
develop systemic AIDs that have been related to impaired develop-
ment, survival, and function of CD4+ Treg cells (1, 31). However,
the lack of IL-2 signaling effects on CD8+ Tregs has not been
specifically evaluated in these models. Nevertheless, it is already
known that, like CD4+ Tregs, CD8+ Tregs expand in response
to IL-2 treatment, as we previously showed in a clinical trial using
low-dose IL-2 in hepatitis C virus-induced vasculitis (32) and type
1 diabetes (33).
We sought to characterize CD8+CD25+FOXP3+ Tregs in mice
and humans, phenotypically and functionally, at steady state and
under IL-2 stimulation in vitro and in vivo. We show here that
CD8+ Tregs are highly suppressive and responsive to IL-2. Our
results warrant further study of these bona fide CD8+ Tregs in
AID pathophysiology and therapy.
MATERIALS AND METHODS
HUMAN BLOOD SAMPLES
Blood samples from healthy volunteers were obtained from the
Etablissement français du sang (EFS) at the Pitié-Salpêtrière Hos-
pital in Paris, France. Informed consent was obtained from each
volunteer.
Blood samples from type 1 diabetes patients were obtained
from the DF-IL2 trial (clinicaltrials.gov identifier NCT01353833).
Patients were treated at the Centre d’Investigation Clinique (CIC)-
Paris Est of la Pitié-Salpêtrière Hospital in Paris, France. Details
about the clinical trial and the patients’ clinical characteristics are
described in Hartemann et al. (34). Written informed consent
was obtained from all participants before enrolment in the study.
The study was approved by the institutional review board of the
Pitié-Salpêtrière Hospital, and was done in accordance with the
Declaration of Helsinki and good clinical practice guidelines.
MICE
BALB/cJRj and C57Bl/6 mice were from Janvier. Transgenic
C57Bl/6 FOXP3-GFP mice that express green fluorescent pro-
tein (GFP) in FOXP3+ cells were kindly provided by Dr. Malis-
sen of the Centre d’immunologie de Marseille Luminy (France).
CD3 KO mice were from CDTA of Orléans (France). Animals
were maintained in our animal facility under specific pathogen-
free conditions in agreement with current European legislation
on animal care, housing, and scientific experimentation. All
procedures were approved by the Regional Ethics Committee
on Animal Experimentation No. 5 of the Ile-de-France region
(Ce5/2012/031).
Preparation of tissue-infiltrating lymphocytes in mice
Spleen, lymph nodes (LNs) (mesenteric LN, MLN; cervical LN,
CLN; pancreatic LN, PaLN), and Peyer’s patches (PP) were isolated
and dissociated in PBS 3% fetal calf serum (FCS). Pancreas was
digested with collagenase/DNase solution in RPMI medium, and
filtered as described (35). A Ficoll (Sigma-Aldrich) gradient was
used to isolate tissue-infiltrating lymphocytes.
Interleukin-2 treatment in mice
Eight-week-old female BALB/c mice received intraperitoneal
injections of 50,000 or 100,000 IU of recombinant human IL-2
(Proleukin, Novartis) or PBS daily for 5 days. Twenty-four hours
after the last injection, blood was collected and analyzed by flow
cytometry.
FLOW CYTOMETRY
Analysis of cell surface and intracellular markers and FOXP3
expression in mice
Fresh total cells from the respective tissues were directly stained
with the following monoclonal antibodies (mAbs) at prede-
termined optimal dilutions for 20 min at 4°C: CD3-PE, CD8-
Alexa700, CD4-HorizonV500, CD127-FITC, and CD25-PeCy7
(eBioscience). Intracellular detection of FOXP3 (FOXP3-E450,
eBioscience), CTLA-4 (CTLA-4-APC, eBioscience), Ki-67 (Ki-67-
FITC, BD Pharmingen), and Bcl-2 (Bcl-2-PE, BD Pharmingen)
was performed on fixed and permeabilized cells using appropri-
ate buffer (eBioscience) (incubation 30 min at 4°C). Cells were
acquired on an LSR II flow cytometer (Becton Dickinson) and
analyzed using FlowJo software (Tree Star, Inc.). Dead cells were
excluded by forward/side scatter gating.
Analysis of cell surface markers and FOXP3 expression in humans
Direct ex vivo immunostaining was performed on 50µL of lithium
heparinized fresh whole blood from healthy donors using the
PerFix-nc kit (Beckman Coulter) according to the manufacturer’s
instructions. Briefly, 5µL of fixative reagent was added to the
blood for 15 min at room temperature in the dark, before adding
antibodies diluted in 300µL of permeabilizing reagent for 1 h
at room temperature in the dark. Staining was performed with
FOXP3− AF647 (clone 259D), CD25-PE, CD127-PE-Cy7, CD8-
Chrome Orange, CD4-Pacific Blue, CD3-FITC, CD103-APC,
ICOS-FITC, CD122-FITC, and CCR7-PE mAbs, all from Beckman
Coulter. CTLA-4-PeCy7 mAb was from Biolegend. Samples were
acquired on a Navios cytometer (Beckman Coulter) and analy-
ses were performed using Kaluza software (Beckman Coulter).
Matched mouse isotype control antibodies were used.
Instrument settings (gain, compensation, and threshold) were
set with machine software (Navios Software; Beckman Coulter)
in conjunction with calibration beads (Flow-set beads, Cytocomp
kit, and CYTO-TROL Control Cells). Machine reproducibility was
verified with standardized beads (Flow-check).
In mice and in humans, CD4+ Tregs were defined as CD25+
FOXP3+ cells among CD4+ T cells, and effector CD4+ T cells
as FOXP3− cells among CD4+ T cells. CD8+ Tregs were defined
as CD25+FOXP3+ cells among CD8+ T cells, and effector CD8+
T cells as FOXP3− cells among CD8+ T cells.
Absolute numbers of CD8+ Tregs and CD4+ Tregs in peripheral blood
Briefly, PBMC subsets (CD4+ Tregs, CD8+ Tregs) counts
(cells/µL) were established from fresh blood samples using
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Flowcount fluorescents beads (Beckman Coulter) as internal
standard (33).
pSTAT5 staining procedure
The pSTAT5 staining was assessed using PerFix EXPOSE reagents
from Beckman Coulter as previously described (36). Briefly, fresh
lithium heparinized whole blood was stained using anti-CD4,
anti-CD25, anti-FOXP3, and PE-conjugated anti-phosphorylated
STAT5 (Beckman Coulter) antibodies. Blood samples were stimu-
lated with increasing hIL-2 (proleukin, Novartis) concentrations at
37°C for 10 min. Cell surface staining was then performed. Whole
blood was incubated for 5 min (37°C, incubator). Samples were
fixed for 10 min at room temperature in the dark, using 50µL
of fixative reagent (PerFix EXPOSE). Aliquots were permeabilized
using 1 mL of permeabilizing reagent (PerFix EXPOSE), and incu-
bated for 5 min at 37°C. Samples were centrifuged at 300× g for
5 min, and the supernatant was completely discarded by aspira-
tion. Then, intracellular staining with a mixture of 100µL of stain-
ing reagent including PE-anti-pSTAT5 and AF647-anti-FOXP3
antibodies was performed for 30 min (room temperature) and cells
were washed with 3 mL of washing buffer (PerFix EXPOSE). The
supernatant was completely discarded by aspiration and 300µL
of PBS was added.
IN VITRO SUPPRESSION ASSAY
Four C57Bl/6 FOXP3-GFP mice were sacrificed, and spleen and
LN were collected and dissociated in PBS 3% FCS. Cells were
stained with CD3, CD4, CD8, and CD25 (as described above)
and then sorted using a FACS ARIA cell sorter (Becton Dick-
inson). CD4+GFP− (CD4+ Teffs), CD4+CD25+GFP+ (CD4+
Tregs), and CD8+CD25+GFP+ (CD8+ Tregs) were collected.
The purity of cell preparations exceeded 97%. CD4+ Teffs were
cultured in RPMI 1640 medium supplemented with 5% FCS,
2 mmol/L l-glutamine, 100 U/mg/mL penicillin/streptomycin at
5× 104 cells/well, and variable numbers of regulatory cells were
added in the presence of 7.5× 104 total splenocytes from CD3 KO
mice and anti-CD3 (final concentration 0.1µg/mL, BioXell).
3H-thymidine (1µCi/well) incorporation was evaluated dur-
ing the final 16 h of the 3-day culture.
STATISTICAL ANALYSES
Statistical significance was evaluated using GraphPad Prism ver-
sion 5.00 for Windows (GraphPad Software, San Diego, CA, USA,
http://www.graphpad.com) and calculated using the paired t -
test, Mann–Whitney test (comparison of means, unpaired test,
non-parametric test, two-tail p value), or one-way ANOVA test,
with p< 0.05 (*) taken as statistical significance (**p< 0.01,
***p< 0.001, NS, non-significant).
RESULTS
CHARACTERIZATION AND PHENOTYPE OF CD8+CD25+FOXP3+ Tregs
We measured the percentages and absolute numbers of CD8+
Tregs and CD4+ Tregs in human blood and in blood and lym-
phoid organs from C57Bl/6 and BALB/c mice. A representative
gating strategy for CD8+CD25+FOXP3+ Treg immunopheno-
typing by flow cytometry in humans (Figure 1A) and in BALB/c
mice (Figure 1B) is shown in Figure 1. In mice, CD4+ Tregs and
CD8+ Tregs were solely defined by the co-expression of FOXP3
and CD25. In human and to a lesser extent in mouse, CD4+ Tregs
and CD8+ Tregs were also characterized by low levels of CD127
compared to Teffs (Figure S1 in Supplementary Material).
In peripheral blood mononuclear cells (PBMCs) from human
healthy donors, the percentage of CD8+ Tregs among CD8+
T cells was variable and below 1% (0.38± 0.26, mean± SD,
n= 37; Figure 2A). It is noteworthy that a wide range of values
was observed (0.1–1%) with a quite heterogeneous distribution,
since few individuals had markedly higher values (Figure 2A).
In comparison, the percentage of CD4+ Tregs among CD4+ T
cells in human blood was higher and less variable (8.3± 1.6)
(Figure 2C).
In mice, the percentages of CD8+ Tregs among CD8+ T cells
were 0.07± 0.04 and 0.12± 0.07% in peripheral blood of C57Bl/6
and BALB/c (Figure 2A). Similar or slightly higher values were
observed in spleen and CLN in both mouse strains. When MLN
and PP were analyzed, two to threefold higher values were observed
as compared with blood values, except for PP in BALB/c mice. In
comparison, in these different lymphoid tissues, the percentages
of CD4+ Tregs among CD4+ T cells were around 50-fold higher
in both C57Bl/6 and BALB/c mice (Figure 2C).
These 50-fold differences in percentages of CD4+ Tregs and
CD8+ Tregs were also observed when looking at absolute numbers
(Figures 2B,D) in both human and mouse.
We compared the phenotype of mouse CD8+ Tregs with that
of other CD8+ T cells and of CD4+ T cells, focusing mainly on
proteins associated with the regulatory function of CD4+ Tregs
(Figure 3). Most CD8+ Tregs expressed CD103 (85.2± 11.8%)
and some were CD122+ (11.9± 9.6%) with significantly higher
levels compared with CD8+ Teffs only for CD103 expression
(p< 0.0001). Approximately 36% of them were ICOS+ and only
9% expressed more CTLA-4 than CD8+ Teffs (p< 0.0001 and
p= 0.0025, respectively). CD8+ Tregs had a proliferation rate
measured by expression of Ki-67 (19.8± 11.7%) that was more
than three times higher than that of CD8+ Teffs (6.6± 2.0%,
p< 0.0001), whereas anti-apoptotic Bcl-2 marker expression was
the same in CD8+ Tregs and CD8+ Teffs. This phenotype was
similar in CD4+ Tregs, except for a lower expression of CD103,
CD122, and ICOS (Figure 3).
A large fraction of human CD8+ Tregs express CTLA-4
(59± 19%) (Figure S2 in Supplementary Material) as do CD4+
Tregs. In contrast, CD8+ Tregs do not express any of the other
markers we tested, i.e., CD103, CD122, ICOS, and CCR7 (data not
shown).
SUPPRESSIVE ACTIVITY OF CD4+ Tregs AND CD8+ Tregs
We next evaluated the suppressive capacity of CD8+ Tregs. For
that purpose, we used C57Bl/6 FOXP3-GFP mice. In these knock-
in mice, GFP is expressed only in FOXP3 positive cells and can
thus be used as a marker for flow cytometry sorting of viable
CD8+ Tregs. CD8+ Tregs (CD8+CD25+GFP+) and CD4+ Tregs
(CD4+CD25+GFP+) were sorted and evaluated for their capacity
to suppress CD4+ Teffs (CD4+GFP− cells). CD8+ Tregs appeared
slightly more suppressive than CD4+ Tregs (Figure 4). At a 1:1
Treg:Teff ratio, 95% of CD4+ Teff suppression was observed with
CD8+ Tregs and 77% with CD4+ Tregs. Similar differences were
observed at a 1:2 ratio in the same experiment and similar results
were also obtained with human CD8+ Tregs (28).
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FIGURE 1 | Representative flow cytometry analysis of CD4+ Tregs and CD8+ Tregs from fresh heparinized peripheral blood of human healthy donors
[human (A)] and of naive BALB/c mice [mouse (B)]. CD4+ and CD8+ T cells were gated from CD3+ lymphocytes.
IN VITRO SENSITIVITY TO IL-2 OF CD4+ Tregs AND CD8+ Tregs
As CD4+ Tregs and CD8+ Tregs constitutively express CD25,
included in the high-affinity IL-2 receptor, we investigated
their sensitivity to in vitro IL-2 activation. We evaluated the
IL-2-induced phosphorylation of STAT5 proteins (pSTAT5) by
flow cytometry (Figure 5). CD4+ Tregs are exquisitely sensitive
to IL-2 activation, activated with doses 20- to 40-fold lower than
those required to activate CD4+ Teffs. It is noteworthy that CD8+
Tregs had the same 20- to 40-fold higher sensitivity to IL-2 activa-
tion as CD8+ Teffs, but were 2- to 4-fold less sensitive than CD4+
Tregs (Figure 5A). At 1 IU/mL, the proportion of pSTAT5 posi-
tive cells was of 77.7± 3.8% in CD4+ Tregs, 29.1± 5.2% in CD8+
Tregs, but only 2.9± 0.5 and 1.2± 0.3% in CD4+ and CD8+ Teffs,
respectively. At 10 IU/mL, these proportions were 91.9± 1.5% for
CD4+ Tregs, 46.0± 6.0% for CD8+ Tregs, and only 13.4± 2.4%
for CD4+ Teffs and 4.7± 1.7% for CD8+ Teffs. These differences
in IL-2-induced activation in CD4+ Tregs and CD8+ Tregs can be
correlated with twofold higher levels of CD25 basal expression in
CD4+ Tregs compared with CD8+ Tregs (Figure 5B).
IN VIVO SENSITIVITY TO IL-2 OF CD4+ Tregs AND CD8+ Tregs
We next assessed the dynamics of CD4+ Tregs and CD8+ Tregs
under low-dose IL-2 treatment, which is known to expand and
activate CD4+ Tregs. Seven patients with type 1 diabetes received
3 MIU of IL-2/day for 5 days (34). This led to a significant increase
of CD8+ Tregs, which reached 6.7± 4.3-fold at day 5 (Figure 6A).
This CD8+ Treg expansion was not sustained at day 15, i.e., 10 days
after the last IL-2 injection. IL-2 had a less pronounced effect on
CD4+ Tregs, reaching a 1.8± 0.7-fold expansion at day 5. Never-
theless, and unlike CD8+ Tregs, this increase was sustained until
day 15 (1.8± 0.6-fold). Interestingly, CD25 mean fluorescence
intensity (MFI) was increased both on CD8+ Tregs and CD4+
Tregs after 5-day IL-2 treatment (Figure 6B). This CD25 increase
was slightly higher for CD4+ Tregs than for CD8+ Tregs (2.1± 0.3
versus 1.6± 0.4; p= 0.005).
In BALB/c mice injected daily for 5 days with 50,000 or
100,000 IU of IL-2, we observed a similar dose-dependent increase
of percentages of CD4+ and CD8+ Tregs in peripheral blood
as compared with controls injected with PBS (Figure 7A). A
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FIGURE 2 | Percentages and absolute counts of CD8+ Tregs among CD8+
T cells [respectively (A,B)], and of CD4+ Tregs among CD4+ T cells
[respectively (C,D)] in human healthy donors and C57Bl/6 or BALB/c
naive mice. Human data are from 10 to 37 healthy blood donors. Mouse data
are from a pool of at least three different experiments analyzing 8- to
12-week-old female mice. Individual values and mean±SEM are shown.
MLN, mesenteric lymph nodes; CLN, cervical lymph nodes; PP, Peyer’s
patches.
5-day course of 50,000 IU of IL-2 led to a 1.5± 0.3-fold increase
of CD4+ Tregs and 1.5± 0.6-fold increase of CD8+ Tregs. At
100,000 IU/day, the increase was 1.9± 0.1-fold for CD4+ Tregs
and 1.8± 0.5-fold for CD8+ Tregs. Similarly to the human study,
we observed an IL-2 dose-dependent increase of CD25 expres-
sion in both CD4+ Tregs and CD8+ Tregs (Figure 7A). The fold
increase of CD25 MFI induced by 50,000 or 100,000 IU of IL-2 was
1.4± 0.2 or 1.8± 0.2 in CD4+ Tregs and 1.3± 0.4 or 1.8± 0.5
in CD8+ Tregs, respectively. In contrast, FOXP3 expression lev-
els were slightly increased only in CD4+ Tregs (1.1± 0.1 both
with 50,000 and 100,000 IU of IL-2). No significant differences in
FOXP3 expression level were observed in CD8+ Tregs at the two
doses.
We also monitored some activation and proliferation mark-
ers in CD4+ Tregs and CD8+ Tregs after a 5-day course of
50,000 IU of IL-2. Interestingly, CD103, CTLA-4, ICOS, Ki-67,
and Bcl-2 expression levels were increased after IL-2 treatment
in CD4+ Tregs but not in CD8+ Tregs (Figure 7B and represen-
tative stainings in Figure S2 in Supplementary Material). These
results highlight the specific biology of CD8+ Tregs compared
with conventional CD4+ Tregs.
DISCUSSION AND CONCLUSION
ON BONA FIDE CD8+ Tregs
CD8+ Tsups are heterogeneous and often poorly characterized
if not controversial cells in mice and humans. We focused our
study on CD8+CD25+FOXP3+ T cells, which we call CD8+
Tregs, because they are identified based on the same markers as
CD4+ Tregs. CD8+ Tregs are present at steady state at low lev-
els both in human and mouse peripheral blood (about 0.4 and
0.1%, respectively). We previously reported lower percentages of
CD8+ Tregs in blood of normal volunteers (0.22± 0.1%) (28),
but we were using a different flow cytometry staining strategy.
Because we optimized our flow cytometry analyses (choice of anti-
bodies, analyses of whole blood with Perfix-NC kit), we believe
that our new values accurately reflect their percentages. Natural
CD8+CD25+FOXP3+ T cells are also present at very low frequen-
cies (between 0.3 and 1.8% in CD8+ T cells) in blood, LNs, thymus,
and spleen from naive non-human primates (37, 38).
We report here that CD8+ Tregs, as CD4+ Tregs, constitutively
express CD25 and are sensitive to in vitro IL-2 activation, to which
they respond by STAT5 phosphorylation. Like CD4+ Tregs, CD8+
Tregs also express markers associated with CD4+ Treg suppressive
activity such as ICOS (39), CD103 (40, 41), and CTLA-4 (42, 43)
at higher levels than other CD8+ T cells. It is of note that nearly
80% of CD8+ Tregs are CD103+, a marker associated with sup-
pressive function of CD8+ T cells (21, 40, 44). This phenotype is
associated with a high suppressive activity in vitro in classic func-
tional assays. Similar suppressive activities of CD8+ Tregs have
also been reported in humans (28) and non-human primates (45).
Altogether, CD8+FOXP3+CD25+ T cells share phenotypic and
functional characteristics with thymic CD4+ Tregs and are thus
bona fide CD8+ Tregs, a designation that should be restricted to
this population.
As for CD4+ Tregs, it seems that there could be a popula-
tion of induced CD8+ Tregs. CD8+Foxp3+ can be induced ex
vivo from CD8+Foxp3− cells after culture in the presence of IL-2
and TGF-beta, but are only mildly suppressive (45, 46). Following
simian immunodeficiency virus (SIV) infection, these periph-
eral CD8+CD25+Foxp3+ regulatory T cells are largely induced
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FIGURE 3 | Phenotypic characterization of CD8+CD25+FOXP3+ Tregs
(CD8+ Tregs) compared with CD8+CD25−FOXP3− effector CD8+ T cells
(CD8+ Teffs) and with CD4+CD25+FOXP3+ Tregs (CD4+ Tregs) in female
BALB/c mice. Representative histograms showing expression of CD103,
CTLA-4, Ki-67, CD122, ICOS, and Bcl-2 in CD8+ Teffs (gray) and in CD8+ Tregs
(black) compared to isotype control (white) are shown. Corresponding
percentages in the overall population are shown. Individual values and
mean±SEM are shown.
FIGURE 4 | Suppressive activity of murine CD4+ Tregs and CD8+ Tregs.
Freshly sorted CD4+GFP− (CD4+ Teffs) cells were cultured with CD4+ Tregs
or CD8+ Tregs at various ratios for 3 days, and tritiated thymidine was added
for the last 16 h of the culture. Proliferation was assessed by tritiated
thymidine incorporation measurement.
not only in blood but also in colorectal mucosa (37, 38). These
cells have a regulatory phenotype (CD25+, CTLA-4+, CD28+,
CD127−) (26, 28) with high proliferative capacities as 60% of
induced CD8+ Tregs are Ki-67+. They express low levels of
granzyme B and perforin, suggesting that their suppression is not
mediated by killing.
ON DIFFERENCES BETWEEN CD4+ Tregs AND CD8+ Tregs
While CD8+ Tregs and CD4+ Tregs share functional suppres-
sive activity, differences in their biology have been reported. IL-2
can bind the high-affinity trimeric IL-2 receptor (IL-2R) (CD25,
CD122, and CD132) or the low-affinity dimeric IL-2R (CD122 and
CD132) (47, 48). The trimeric IL-2R is constitutively expressed on
CD4+ Tregs, but only transiently expressed on CD4+ and CD8+
T cells following T cell receptor (TCR) activation (47). We show
here that CD8+ Tregs constitutively express the trimeric IL-2R, but
compared with CD4+ Tregs, CD8+ Tregs express fewer CD25 mol-
ecules on their cell surface. CD4+ Tregs are two to fourfold more
sensitive to IL-2 activation than CD8+ Tregs, although both CD4+
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FIGURE 5 | Foxp3+ CD25high CD127low CD4+ T cells (CD4+ Tregs) and
Foxp3+ CD25high CD127low CD8+ T cells (CD8+ Tregs) responsiveness to IL-2
and their comparative CD25 cell surface expressions. (A) Total fresh blood
from healthy donors was ex vivo stimulated with different doses of IL-2 for
10 min, and STAT5 phosphorylation was measured on different T cell subsets.
Results are expressed in mean±SE, n=7–22. Low-dose IL-2 has been
defined as the dose inducing high STAT5 phosporylation on CD4+ Tregs but
not on CD4+ Teff. (B) Mean fluorescence intensity (MFI) of CD25 on CD4+
Tregs and CD8+ Tregs (n=37) from fresh unstimulated whole blood from
healthy donors. Individual values and mean±SEM are shown.
FIGURE 6 | Effects of low-dose IL-2 on Foxp3+ CD25high CD127low
CD4+ T cells (CD4+ Tregs) and Foxp3+ CD25high CD127low CD8+ T
cells (CD8+ Tregs) in humans. Seven type 1 diabetes patients were
treated with 3 MIU IL-2/day for 5 days (34). Time-course changes of
CD8+ Tregs and CD4+ Tregs percentages in peripheral blood (A) and
of CD25 mean fluorescence intensity (MFI) in CD8+ Tregs and CD4+
Tregs in peripheral blood (B) following a 5-days course of low-dose
IL-2. Individual values and mean±SEM are shown. Results are
expressed in fold variation compared with the mean at day 0 of all the
samples.
and CD8+ Tregs are equally 20 times more sensitive to IL-2 than
their FOXP3− counterparts. However, despite these differences in
favor of CD4+ Tregs in vitro, we observed that the sensitivity of
CD8+ Tregs to IL-2 in vivo is higher than that of CD4+ Tregs
(Figure 6A), a so far unexplained observation. In agreement with
our observations, a very large increase of CD8+ Tregs, greater than
that for CD4+ Tregs, has been observed in blood of non-human
primates following IL-2 treatment (49) in a context of tuberculosis
infection.
Upon IL-2 activation, CD25 up-regulation is lower for CD8+
than for CD4+ Tregs. Also, after IL-2 treatment, activation markers
such as CD103, CTLA-4, and ICOS, which are increased in CD4+
Tregs, are not increased in CD8+ Tregs, suggesting that IL-2 regu-
lates CD8+ Tregs differently than CD4+ Tregs. Further studies are
needed to clarify the molecular effects of IL-2 on CD8+ Tregs.
Importantly, we showed that CD8+ Tregs suppress in vitro
effector T cell proliferation as well as or even better than CD4+
Tregs. This experiment has been performed only in mice as for
now the low number of bona fide CD8+ Tregs in peripheral
blood from human healthy donors does not allow to perform
suppressive assays with these cells. However, we have already
showed that non-manipulated human cord blood CD8+ Tregs
are suppressive (50). It has also been reported that CD8+ Tregs
from healthy non-human primates suppress as well as CD4+
Tregs (45). Thus, we can assume that, even if CD8+ Tregs
are less numerous than CD4+ Tregs in peripheral blood of
human healthy donors, their excellent suppressive activity makes
them important cells to consider in the regulation of immune
responses.
For now, it has previously shown by others and us that in vivo
IL-2 expanded CD4+ Tregs have better in vitro suppressive activ-
ities than non-expanded CD4+ Tregs. It remains to evaluate
whether this is also true for CD8+ Tregs functions.
ON THE POSSIBLE ROLE OF CD8+ Tregs
Several mechanisms have been implicated in the suppressive activ-
ity of suppressive CD8+ T cells, including direct lysis of target cells
and secretion of immunosuppressive cytokines (14).
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FIGURE 7 | Effects of low-dose IL-2 on CD4+ Tregs and CD8+ Tregs in
mice. Eight-week-old female BALB/c mice were injected daily for
5 days with PBS or with 50,000 or 100,000 IU of IL-2, and blood was
sampled after the treatment. (A) Relative variations of percentages,
CD25 MFI and FOXP3 MFI of CD4+ Tregs and CD8+ Tregs in blood after
treatment (pool of three independent experiments). Individual values
and mean±SEM are shown. (B) Phenotypic activation markers of
CD4+ Tregs and CD8+ Tregs after 5-day course of PBS (PBS) or
50,000 IU of IL-2 (IL-2) (pool of two independent experiments).
Individual values and mean±SEM are shown.
CTLA-4 has been shown to play a role in cell–cell contact-
dependent mechanisms of CD4+ Tregs and CD8+ Treg-mediated
suppression (51). As CD4+ Tregs, CD8+ Tregs may impede the
up-regulation of CD80 and CD86 on immature dendritic cells or
down-modulate them on mature dendritic cells (42) via CTLA-4,
thereby inhibiting activation of Teffs. Jebbawi et al. (50) described
a similar natural CD8+ Treg population from cord blood. This
population expresses CTLA-4 and can secrete IL-10 and TGF-beta
compared with CD8+CD25− T cells.
CD8+ Tregs have also been implicated in the regulation of
human AID, including inflammatory bowel disease (22). Euse-
bio et al. (52) showed also that asthma patients have fewer CD8+
Tregs in blood than healthy control subjects. Furthermore, FOXP3
mRNA levels of CD8+ T cells were significantly decreased in
patients with severe asthma compared with mild to moderate
asthma and control patients. Thus, natural CD8+ Tregs could play
a major role in control of allergic inflammation.
In cancer, Chaput et al. (28) and Kiniwa et al. (53) demonstrated
that CD8+ Tregs from colorectal and prostate tumors have strong
immunosuppressive properties, and may contribute to tumoral
immune escape and disease progression.
As many groups have reported the presence of CD8+ Tregs after
induction either by a drug or by pathological conditions (AIDs,
cancer, infection, allergy), it remains to be seen in these models
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whether they are induced by pathological or natural conditions.
In any case, we demonstrate here that bona fide CD8+ Tregs are
present at steady state in mice and humans.
CONCLUSION
Many questions remain, especially about the origin and role of
natural CD8+ Tregs in health and disease. Their striking phe-
notypic similarities with CD4+ Tregs, robust suppressive activity
in vitro and exquisite sensitivity to IL-2 warrant further studies to
fully appreciate their clinical relevance in AIDs and inflammatory
diseases, and in IL-2 treatment efficacy.
ACKNOWLEDGMENTS
This work was supported by French state funds managed by
the ANR within the Investissements d’Avenir programme under
reference ANR-11-IDEX-0004-02. The authors thank Beckman
Coulter and especially Fabrice Malergue and Olivier Jaen (Beck-
man Coulter employees) for their technical support. PSTAT5-PE
antibody was kindly provided by Beckman Coulter. The authors
also thank Charlotte Pouchy (UPMC UMRS CR7 – INSERM
U1135), Michèle Barbie (AP-HP), and Bruno Gouritin (UPMC
CNRS UMR 7211) for their technical support in the suppression
experiments.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://journal.frontiersin.org/article/10.3389/fimmu.2015.00171
REFERENCES
1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune
tolerance. Cell (2008) 133:775–87. doi:10.1016/j.cell.2008.05.009
2. Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8
T cells. Cell Mol Immunol (2005) 2:11–9.
3. Yang M, Rui K, Wang S, Lu L. Regulatory B cells in autoimmune diseases. Cell
Mol Immunol (2013) 10:122–32. doi:10.1038/cmi.2012.60
4. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains
(CD25). Breakdown of a single mechanism of self-tolerance causes various
autoimmune diseases. J Immunol (1995) 155:1151–64.
5. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-
tolerance and negative control of immune responses. Annu Rev Immunol (2004)
22:531–62. doi:10.1146/annurev.immunol.21.120601.141122
6. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L,
et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 27:20–1.
doi:10.1038/83713
7. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. CD8+ Tregs in lupus,
autoimmunity, and beyond. Autoimmun Rev (2010) 9:560–8. doi:10.1016/j.
autrev.2010.03.006
8. Pomié C, Ménager-Marcq I, van Meerwijk JPM. Murine CD8+ regulatory T
lymphocytes: the new era. Hum Immunol (2008) 69:708–14. doi:10.1016/j.
humimm.2008.08.288
9. Sinha S, Itani FR, Karandikar NJ. Immune regulation of multiple sclero-
sis by CD8+ T cells. Immunol Res (2014) 59:254–65. doi:10.1007/s12026-014-
8529-9
10. Salgame P, Convit J, Bloom BR. Immunological suppression by human CD8+
T cells is receptor dependent and HLA-DQ restricted. Proc Natl Acad Sci U S A
(1991) 88:2598–602. doi:10.1073/pnas.88.6.2598
11. Inoue T, Asano Y, Matsuoka S, Furutani-Seiki M, Aizawa S, Nishimura H, et al.
Distinction of mouse CD8+ suppressor effector T cell clones from cytotoxic
T cell clones by cytokine production and CD45 isoforms. J Immunol (1993)
150:2121–8.
12. Wang YM, Alexander SI. CD8 regulatory T cells: what’s old is now new. Immunol
Cell Biol (2009) 87:192–3. doi:10.1038/icb.2009.8
13. Kim H-J, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper
cells by CD8(+) regulatory T cells is essential for self tolerance. Nature (2010)
467:328–32. doi:10.1038/nature09370
14. Lu L, Cantor H. Generation and regulation of CD8(+) regulatory T cells. Cell
Mol Immunol (2008) 5:401–6. doi:10.1038/cmi.2008.50
15. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, et al.
Reversal of autoimmunity by boosting memory-like autoregulatory T cells.
Immunity (2010) 32:568–80. doi:10.1016/j.immuni.2010.03.015
16. Suzuki M, Konya C, Goronzy JJ, Weyand CM. Inhibitory CD8+ T cells in
autoimmune disease. Hum Immunol (2008) 69:781–9. doi:10.1016/j.humimm.
2008.08.283
17. Jiang H, Zhang SI, Pernis B. Role of CD8+ T cells in murine experimental
allergic encephalomyelitis. Science (1992) 256:1213–5. doi:10.1126/science.256.
5060.1213
18. Tada Y, Ho A, Koh DR, Mak TW. Collagen-induced arthritis in CD4- or CD8-
deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase
of collagen-induced arthritis. J Immunol (1996) 156:4520–6.
19. Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M, et al. Impairment
of CD8+ T suppressor cell function in patients with active systemic lupus ery-
thematosus. J Immunol (2001) 166:6452–7. doi:10.4049/jimmunol.166.10.6452
20. Tulunay A, Yavuz S, Direskeneli H, Eksioglu-Demiralp E. CD8+CD28-, sup-
pressive T cells in systemic lupus erythematosus. Lupus (2008) 17:630–7.
doi:10.1177/0961203308089400
21. Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regula-
tory T cell (Treg) subsets return in patients with refractory lupus following
stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associ-
ated with immunological remission of lupus. J Immunol (2009) 183:6346–58.
doi:10.4049/jimmunol.0901773
22. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8+
regulatory T cells in the lamina propria of patients with inflammatory bowel
disease. J Immunol (2005) 174:5814–22. doi:10.4049/jimmunol.174.9.5814
23. Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman EM,
et al. Neuroantigen-specific CD8+ regulatory T-cell function is deficient dur-
ing acute exacerbation of multiple sclerosis. J Autoimmun (2011) 36:115–24.
doi:10.1016/j.jaut.2010.12.003
24. Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple
sclerosis. Ann Neurol (2010) 67:625–38. doi:10.1002/ana.21944
25. Frisullo G, Nociti V, Iorio R, Plantone D, Patanella AK, Tonali PA, et al.
CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple
sclerosis patients. Hum Immunol (2010) 71:437–41. doi:10.1016/j.humimm.
2010.01.024
26. Kreft KL, Verbraak E, Wierenga-Wolf AF, Laman JD, Hintzen RQ. Role of CD8
regulatory T-cells in multiple sclerosis. Ann Neurol (2011) 69:593. doi:10.1002/
ana.22288
27. Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus
mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant,
TGFbeta-secreting CD8+ T cell suppressors. J Immunol (2005) 175:7728–37.
doi:10.4049/jimmunol.175.11.7728
28. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant J-C, Ménégaux F, et al. Iden-
tification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Gut (2009) 58:520–9. doi:10.1136/gut.2008.158824
29. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH. CD8+ T cell-mediated sup-
pression of autoimmunity in a murine lupus model of peptide-induced immune
tolerance depends on Foxp3 expression. J Immunol (2007) 178:7649–57.
doi:10.4049/jimmunol.178.12.7649
30. Singh RP, La Cava A, Hahn BH. pConsensus peptide induces tolerogenic CD8+
T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3
and PD1 molecules. J Immunol (2008) 180:2069–80. doi:10.4049/jimmunol.
180.4.2069
31. Malek TR. The biology of interleukin-2. Annu Rev Immunol (2008) 26:453–79.
doi:10.1146/annurev.immunol.26.021607.090357
32. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory
T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J
Med (2011) 365:2067–77. doi:10.1056/NEJMoa1105143
33. Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, et al. Low-
dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in
T1D patients. J Autoimmun (2015) 58:48–58. doi:10.1016/j.jaut.2015.01.001
34. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas
N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2
www.frontiersin.org April 2015 | Volume 6 | Article 171 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Churlaud et al. CD8+ Tregs and IL-2 therapy
randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol
(2013) 1:295–305. doi:10.1016/S2213-8587(13)70113-X
35. Churlaud G, Jimenez V, Ruberte J, Amadoudji Zin M, Fourcade G, Gottrand G,
et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmu-
nity without impairing immune responses to infection, vaccination and cancer.
Clin Immunol (2014) 151:114–26. doi:10.1016/j.clim.2014.02.003
36. Dupont G, Demaret J, Venet F, Malergue F, Malcus C, Poitevin-Later F, et al.
Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5
phosphorylation in CD4+FOXP3- cells versus regulatory T cells: a whole blood
perspective. Cytokine (2014) 69:146–9. doi:10.1016/j.cyto.2014.05.021
37. Nigam P, Velu V, Kannanganat S, Chennareddi L, Kwa S, Siddiqui M, et al.
Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal
mucosa following a pathogenic simian immunodeficiency virus infection cor-
relates with diminished antiviral T cell response and viral control. J Immunol
(2010) 184:1690–701. doi:10.4049/jimmunol.0902955
38. Karlsson I, Malleret B, Brochard P, Delache B, Calvo J, Le Grand R, et al.
FoxP3+ CD25+ CD8+ T-cell induction during primary simian immunodefi-
ciency virus infection in cynomolgus macaques correlates with low CD4+ T-cell
activation and high viral load. J Virol (2007) 81:13444–55. doi:10.1128/JVI.
01619-07
39. Ito T, Hanabuchi S, Wang Y-H, Park WR, Arima K, Bover L, et al. Two func-
tional subsets of FOXP3+ regulatory T cells in human thymus and periphery.
Immunity (2008) 28:870–80. doi:10.1016/j.immuni.2008.03.018
40. Koch SD, Uss E, van Lier RAW, ten Berge IJM. Alloantigen-induced regula-
tory CD8+CD103+ T cells. Hum Immunol (2008) 69:737–44. doi:10.1016/j.
humimm.2008.08.281
41. Allakhverdi Z, Fitzpatrick D, Boisvert A, Baba N, Bouguermouh S, Sarfati M,
et al. Expression of CD103 identifies human regulatory T-cell subsets. J Allergy
Clin Immunol (2006) 118:1342–9. doi:10.1016/j.jaci.2006.07.034
42. Oderup C, Cederbom L, Makowska A, Cilio CM, Ivars F. Cytotoxic T lymphocyte
antigen-4-dependent down-modulation of costimulatory molecules on den-
dritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunol-
ogy (2006) 118:240–9. doi:10.1111/j.1365-2567.2006.02362.x
43. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al.
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells
constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp
Med (2000) 192:303–10. doi:10.1084/jem.192.2.303
44. Keino H, Masli S, Sasaki S, Streilein JW, Stein-Streilein J. CD8+ T regulatory
cells use a novel genetic program that includes CD103 to suppress Th1 immu-
nity in eye-derived tolerance. Invest Ophthalmol Vis Sci (2006) 47:1533–42.
doi:10.1167/iovs.04-1454
45. Aoyama A, Klarin D, Yamada Y, Boskovic S, Nadazdin O, Kawai K, et al. Low-
dose IL-2 for In vivo expansion of CD4+ and CD8+ regulatory T cells in non-
human primates. Am J Transplant (2012) 12:2532–7. doi:10.1111/j.1600-6143.
2012.04133.x
46. Mayer CT, Floess S, Baru AM, Lahl K, Huehn J, Sparwasser T. CD8+ Foxp3+ T
cells share developmental and phenotypic features with classical CD4+ Foxp3+
regulatory T cells but lack potent suppressive activity. Eur J Immunol (2011)
41:716–25. doi:10.1002/eji.201040913
47. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation
of the immune system. Nat Rev Immunol (2012) 12:180–90. doi:10.1038/nri3156
48. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between
tolerance and immunity. Immunity (2010) 33:153–65. doi:10.1016/j.immuni.
2010.08.004
49. Chen CY, Huang D, Yao S, Halliday L, Zeng G, Wang RC, et al. IL-2
simultaneously expands Foxp3+ T regulatory and T effector cells and confers
resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation
in immunity to TB. J Immunol (2012) 188:4278–88. doi:10.4049/jimmunol.
1101291
50. Jebbawi F, Fayyad-Kazan H, Merimi M, Lewalle P, Verougstraete J-C, Leo
O, et al. A microRNA profile of human CD8. J Transl Med (2014) 12:218.
doi:10.1186/s12967-014-0218-x
51. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, et al.
Human CD8+CD25+ thymocytes share phenotypic and functional features with
CD4+CD25+ regulatory thymocytes. Blood (2003) 102:4107–14. doi:10.1182/
blood-2003-04-1320
52. Eusebio M, Kraszula L, Kupczyk M, Kuna P, Pietruczuk M. Low frequency of
CD8+CD25+FOXP3(BRIGHT) T cells and FOXP3 mRNA expression in the
peripheral blood of allergic asthma patients. J Biol Regul Homeost Agents (2012)
26:211–20.
53. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+
Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin
Cancer Res (2007) 13:6947–58. doi:10.1158/1078-0432.CCR-07-0842
Conflict of Interest Statement: Guillaume Churlaud, Michelle Rosenzwajg,
Bertrand Bellier, and David Klatzmann are shareholders of ILTOO pharma, a com-
pany with the exclusive license for a patent (of which Michelle Rosenzwajg and
David Klatzmann are the inventors) owned by the authors’ academic institution
and claiming the use of low-dose IL-2 in autoimmune diseases.
Received: 28 November 2014; accepted: 27 March 2015; published online: 15 April 2015.
Citation: Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg
M and Klatzmann D (2015) Human and mouse CD8+CD25+FOXP3+ regulatory
T cells at steady state and during interleukin-2 therapy. Front. Immunol. 6:171. doi:
10.3389/fimmu.2015.00171
This article was submitted to T Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2015 Churlaud, Pitoiset , Jebbawi, Lorenzon, Bellier , Rosenzwajg and
Klatzmann. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Immunology | T Cell Biology April 2015 | Volume 6 | Article 171 | 10
